NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$325.9m

Last Updated

2021/05/13 00:40 UTC

Data Sources

Company Financials +

Executive Summary

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.


Similar Companies

Share Price & News

How has Acutus Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AFIB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: AFIB's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-3.3%

AFIB

-3.6%

US Medical Equipment

-2.8%

US Market


1 Year Return

n/a

AFIB

32.9%

US Medical Equipment

49.4%

US Market

Return vs Industry: Insufficient data to determine how AFIB performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how AFIB performed against the US Market.


Shareholder returns

AFIBIndustryMarket
7 Day-3.3%-3.6%-2.8%
30 Day-7.1%-1.2%-2.3%
90 Day-51.5%-3.3%-1.3%
1 Yearn/a33.9%32.9%51.8%49.4%
3 Yearn/a66.8%62.9%57.5%47.6%
5 Yearn/a148.1%130.0%121.7%97.1%

Long-Term Price Volatility Vs. Market

How volatile is Acutus Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Acutus Medical undervalued compared to its fair value and its price relative to the market?

2.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AFIB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AFIB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AFIB is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: AFIB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AFIB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AFIB is good value based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (4.6x).


Future Growth

How is Acutus Medical forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

10.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AFIB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AFIB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AFIB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AFIB's revenue (68.1% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: AFIB's revenue (68.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AFIB is forecast to be unprofitable in 3 years.


Past Performance

How has Acutus Medical performed over the past 5 years?

-5.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AFIB is currently unprofitable.

Growing Profit Margin: AFIB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AFIB's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AFIB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AFIB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (21.6%).


Return on Equity

High ROE: AFIB has a negative Return on Equity (-80.56%), as it is currently unprofitable.


Financial Health

How is Acutus Medical's financial position?


Financial Position Analysis

Short Term Liabilities: AFIB's short term assets ($151.4M) exceed its short term liabilities ($21.9M).

Long Term Liabilities: AFIB's short term assets ($151.4M) exceed its long term liabilities ($44.0M).


Debt to Equity History and Analysis

Debt Level: AFIB's debt to equity ratio (30.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AFIB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AFIB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AFIB has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 41.5% each year.


Dividend

What is Acutus Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AFIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AFIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AFIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AFIB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AFIB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Vince Burgess (55 yo)

3.58yrs

Tenure

US$532,316

Compensation

Mr. Vincent J. Burgess, also known as Vince, has been President and Chief Executive Officer of Acutus Medical, Inc., since October 2017 and has been its Director since June 2013 and served as its Chairman ...


CEO Compensation Analysis

Compensation vs Market: Vince's total compensation ($USD532.32K) is below average for companies of similar size in the US market ($USD1.73M).

Compensation vs Earnings: Insufficient data to compare Vince's compensation with company performance.


Leadership Team

Experienced Management: AFIB's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: AFIB's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: AFIB only recently listed within the past 12 months.


Top Shareholders

Company Information

Acutus Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acutus Medical, Inc.
  • Ticker: AFIB
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$325.949m
  • Shares outstanding: 28.12m
  • Website: https://www.acutusmedical.com

Number of Employees


Location

  • Acutus Medical, Inc.
  • 2210 Faraday Avenue
  • Suite 100
  • Carlsbad
  • California
  • 92008
  • United States

Listings


Biography

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and inte...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/13 00:40
End of Day Share Price2021/05/12 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.